Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Hannawi S, Wu XH, Villalobos RE, Burhan E, Lallaine Borra MD, Gupta RK, Aquitania GP, Ang BWC, Mae A Zabat G, Roa CC, Zoleta-De Jesus L, Yu DD, Wang M, Wu Y, Song WJ, Ying B, Qin CF. Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial. Med. 2024 Oct 11; 5(10):1282-1292.e3.
-
Ben Hamed S, Myers JF, Chandwani A, Wirblich C, Kurup D, Paran N, Schnell MJ. Toward the Development of a Pan-Lyssavirus Vaccine. Viruses. 2024 Jul 10; 16(7).
-
Bochkov YA, Devries M, Tetreault K, Gangnon R, Lee S, Bacharier LB, Busse WW, Camargo CA, Choi T, Cohen R, De R, DeMuri GP, Fitzpatrick AM, Gergen PJ, Grindle K, Gruchalla R, Hartert T, Hasegawa K, Khurana Hershey GK, Holt P, Homil K, Jartti T, Kattan M, Kercsmar C, Kim H, Laing IA, Le Sou?f PN, Liu AH, Mauger DT, Pappas T, Patel SJ, Phipatanakul W, Pongracic J, Seroogy C, Sly PD, Tisler C, Wald ER, Wood R, Lemanske RF, Jackson DJ, Gern JE. Rhinoviruses A and C elicit long-lasting antibody responses with limited cross-neutralization. J Med Virol. 2023 08; 95(8):e29058.
-
Tebas P, Lynn K, Azzoni L, Cocchella G, Papasavvas E, Fair M, Karanam B, Sharma P, Reeves JD, Petropoulos CJ, Lalley-Chareczko L, Kostman JR, Short W, Mounzer K, Montaner LJ. Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons. AIDS. 2023 Jul 01; 37(8):1203-1207.
-
Qin J, Jeon JH, Xu J, Langston LK, Marasini R, Mou S, Montoya B, Melo-Silva CR, Jeon HJ, Zhu T, Sigal LJ, Xu R, Zhu H. Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine. Front Immunol. 2023; 14:1126392.
-
Piechnik M, Amendum PC, Sawamoto K, Stapleton M, Khan S, Fnu N, ?lvarez V, Pachon AMH, Danos O, Bruder JT, Karumuthil-Melethil S, Tomatsu S. Sex Difference Leads to Differential Gene Expression Patterns and Therapeutic Efficacy in Mucopolysaccharidosis IVA Murine Model Receiving AAV8 Gene Therapy. Int J Mol Sci. 2022 Oct 21; 23(20).
-
Abo Shama NM, Mahmoud SH, Bagato O, AbdElsalam ET, Alkhazindar M, Kandeil A, McKenzie PP, Webby RJ, Ali MA, Kayali G, El-Shesheny R. Incidence and neutralizing antibody seroprevalence of influenza B virus in Egypt: Results of a community-based cohort study. PLoS One. 2022; 17(6):e0269321.
-
Kurup D, Wirblich C, Zabihi Diba L, Lambert R, Watson M, Shaikh N, Ramage H, Solomides C, Schnell MJ. A Single Dose of the Deactivated Rabies-Virus Vectored COVID-19 Vaccine, CORAVAX, Is Highly Efficacious and Alleviates Lung Inflammation in the Hamster Model. Viruses. 2022 May 24; 14(6).
-
Schapiro HM, Khasnis MD, Ahn K, Karagiaridi A, Hayden S, Cilento ME, Root MJ. Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env. PLoS Pathog. 2022 May; 18(5):e1010531.
-
Sievers BL, Chakraborty S, Xue Y, Gelbart T, Gonzalez JC, Cassidy AG, Golan Y, Prahl M, Gaw SL, Arunachalam PS, Blish CA, Boyd SD, Davis MM, Jagannathan P, Nadeau KC, Pulendran B, Singh U, Scheuermann RH, Frieman MB, Vashee S, Wang TT, Tan GS. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci Transl Med. 2022 03 02; 14(634):eabn7842.